Immuno-oncology (IO) is one of the most active area of clinical development. In the past few years, the IO clinical landscape has shifted towards combination trials which are trials that investigate IO therapies in combination with other therapies. To address this shift in the IO clinical trial landscape, Trialtrove has added three new IO combination tags to Trialtrove records that enable easy retrieval of IO combination trials. These tags capture the most common types of IO combination trials:
IO/IO Combination - clinical trials that evaluate the combination of two or more immuno-oncology drugs
IO/Targeted Combination - clinical trials that evaluate the combination of at least one immuno-oncology drug and at least one drug acting via a specific molecular target
IO/Cytotoxic Combination - clinical trials that evaluate the combination of at least one immuno-oncology drug and at least one drug acting as a broad-spectrum, cytotoxic agent
While all relevant Trialtrove records now contain the new IO tags, they are exclusively searchable using the next generation of Trialtrove. To introduce this enhancement, we compiled some key insights about IO combination trials and a visual overview of the IO competitive landscape.
Source: Trialtrove, data retrieved September 14, 2017
Authors: Maria A. Berezina, PhD and Rachel Meighan-Mantha, PhD
Methodology: Combination trials included only those trials evaluating an IO drug or therapy in combination with another drug or therapy. Trials evaluating an IO drug or therapy alone or only with a non-drug intervention such as radiotherapy or surgery were categorized as Monotherapy trials.
Initiation date was used for the charts with "Years".